Abstract:Engineered nanomaterials (such as graphene oxide, GO) have shown great potential in biomedical applications as therapeutic and imaging agents. However, little is known about their potential transformations in biological settings, which may alter their physicochemical properties and consequently hinder their biomedical applications. Here, we show that GO undergoes a significant physicochemical transformation in two simulated human lung fluids–Gamble’s solution and artificial lysosomal fluid (ALF), as the organic acids (e.g., citrate and acetate) in the lung fluids cause the reduction of GO, which is mainly due to the conversion of epoxy and carbonyl groups to phenolic groups. This biotransformation markedly inhibits the endocytosis of GO by scavenging macrophages. Notably, the alterations that occur in Gamble’s solution enhance the layer-by-layer aggregation of GO, resulting in the precipitation of GO and a reduction in its interaction with cells, whereas the changes that occur in ALF lead to edge-to-edge aggregation of GO, thereby enhancing the adhesion of large sheet-like GO aggregates on the plasma membrane without cellular uptake. The varied interaction mechanisms with macrophages eventually induce different proinflammatory reactions. Experiments conducted in mice corroborated the morphological alterations of GO in a realistic lung microenvironment. Overall, the findings suggest that the biotransformation of nanomaterials may significantly alter their inherent properties and therefore affect their biosafety, such as the clearance of “worn-out” nanomaterials by immune cells, giving rise to potentially long-term side effects at the accumulation sites. Graphene-oxide particles inserted into the body for biomedical applications such as drug delivery or enhanced imaging can form aggregates over time with possible adverse effects on health, and show researchers in China. After the medical objectives have been achieved, the nanoparticles often remain inside the human body, but it is unclear what happens to them after long time periods in a biological environment. Sijin Liu from the Chinese Academy of Sciences in Beijing, Wei Chen from Nankai University in Tianjin, and their colleagues show that graphene-oxide nanoparticles undergo a physicochemical transformation in simulated human lung fluids, aggregating to form larger particles. This reduces their interaction with cells and inhibits cellular uptake, and can induce proinflammatory reactions. The results highlight the need to consider the biosafety of nanomaterials and their potential long-term side effects. GO can undergo significant physicochemical transformation in two simulated lung fluids–Gamble’s solution and artificial lysosomal fluid (ALF), as the organic acids in lung fluids cause reduction of GO. Biotransformation markedly inhibits the endocytosis of GO by scavenging macrophages. Notably, alterations in Gamble’s solution enhance the aggregation of GO in a layer-to-layer manner, resulting in GO precipitation and reduced interaction with cells, whereas changes in ALF lead to edge-to-edge aggregation of GO, enhancing the adhesion of large sheet-like GO aggregates on plasma membrane without cellular uptake.

Improved in Vitro and in Vivo Biocompatibility of Graphene Oxide Through Surface Modification: Poly(Acrylic Acid)-Functionalization is Superior to PEGylation.

Surface Coating-Dependent Cytotoxicity And Degradation Of Graphene Derivatives: Towards The Design Of Non-Toxic, Degradable Nano-Graphene

Systematic Assessment of the Toxicity and Potential Mechanism of Graphene Derivatives in Vitro and in Vivo

Fabrication and Biocompatibility Evaluation of Amphiphilic Polymer-decorated Graphene Oxide

Impact of Graphene Oxide on the Structure and Function of Important Multiple Blood Components by A Dose-Dependent Pattern

Better Biocompatibility of Nitrogen-Doped Graphene Compared with Graphene Oxide by Reducing Cell Autophagic Flux Blockage and Cell Apoptosis.

In Vitro Toxicity Evaluation of Graphene Oxide on A549 Cells.

Defining the immunological compatibility of graphene oxide-loaded PLGA scaffolds for biomedical applications

Effects of the Surface Charge of Graphene Oxide Derivatives on Ocular Compatibility

Surface Oxidation of Graphene Oxide Determines Membrane Damage, Lipid Peroxidation, and Cytotoxicity in Macrophages in a Pulmonary Toxicity Model

The Immunotoxicity of Graphene Oxides and the Effect of Pvp-Coating

Biocompatibility of graphene oxide intravenously administrated in mice—effects of dose, size and exposure protocols

Effect of graphene oxide on conformation and activity of catalase

Differential Immunomodulatory Effect of Graphene Oxide and Vanillin-Functionalized Graphene Oxide Nanoparticles in Human Acute Monocytic Leukemia Cell Line (THP-1)

Synthesis and Biocompatibility of Amphiphilic Graphene Oxide

Distribution and Biocompatibility Studies of Graphene Oxide in Mice after Intravenous Administration

The Biotransformation of Graphene Oxide in Lung Fluids Significantly Alters Its Inherent Properties and Bioactivities Toward Immune Cells

Comparative Toxicity of Pristine Graphene Oxide and Its Carboxyl, Imidazole or Polyethylene Glycol Functionalized Products to Daphnia Magna: A Two Generation Study.

Functionalization of graphene oxide generates a unique interface for selective serum protein interactions.

Protein Corona-Mediated Mitigation of Cytotoxicity of Graphene Oxide.

In Vivo Biodistribution and Toxicology of Functionalized Nano-Graphene Oxide in Mice after Oral and Intraperitoneal Administration